In this Pharmaceutical Executive video interview, Edoardo Madussi, Head of Business Development, Intelligencia AI compares the energy consumption of large language models to other technologies or industries.
In this interview, Edoardo Madussi, Head of Business Development, Intelligencia AI discusses the potential impact of AI-driven drug discovery platforms like DeepSeek and Qwen, highlighting their democratizing potential while also acknowledging challenges related to data quality and validation. The conversation explores the potential disruptions to current R&D practices, including the acceleration of drug discovery and the optimization of manufacturing and supply chains.
The discussion also addresses the potential risks associated with relying heavily on open-access AI models, including data security, intellectual property concerns, and the potential for biases in underlying datasets. Finally, the interview touches upon the environmental impact of AI, emphasizing the energy consumption of large language models while acknowledging the potential for AI to improve efficiency and reduce the environmental footprint of drug development.
I think there is no comparison. If you think about the recent news of DeepSeek launching their model, and the all the semiconductor companies that have made a fortune in the last years in generating these very powerful chips, this is probably one of the most highlighted limitations of the evolution of AI, right? The evolution of AI is not because we don't have the science to bring it forward. It's because we don't have the energy, power — we don't have the actual resources, from an energy standpoint, to develop them further.
The limits of AI currently are almost set by the physical limits of our computing power. And so revelations like the ones from DeepSeek, where they may be able to cut down the computing power from an energy perspective, so clearly mark an advancement in the AI innovation. But to your question, no, I don't think there is anything else that compares to this when it comes to really the energy. Maybe Bitcoin, would a comparable environment or a comparable industry where, again, the limitations on the on the adoption of the innovation are set by the physical limits of how much energy we need to have for them to advance.
IMF Chief Medical Officer Discusses Global Initiatives to Improve Myeloma Treatment
August 20th 2024In an interview with Pharm Exec Associate Editor Don Tracy, Joseph Mikhael, chief medical officer, IMF, offers a glimpse at multiple initiatives that the IMF is working towards to improve myeloma treatment globally.
AbbVie Presents New Data from Antibody-Drug Conjugates Across Multiple Indications at ASCO 2024
June 13th 2024In an interview with Pharm Exec Associate Editor Don Tracy, Pedro Valencia, VP, Solid Tumor Pipeline Strategy & Execution, AbbVie, discusses data presented at ASCO from ABBV-400 and ABBV-706 in multiple studies.
Planning for Unique Challenges Faced by Cell & Gene Therapy Developers
May 8th 2024In an interview with Pharm Exec Associate Editor Don Tracy, Melissa Lattanzi, VP, Emerging Therapies, Cencora, discusses the unique challenges that developers of cell and gene therapies need to plan for when building their channel strategy.
Pricing Climate Impacting Commercial Considerations
May 3rd 2024In this Pharmaceutical Executive video interview, Jesse Mendelsohn, senior vice president at Model N, talks about the influence of Medicare Part D drug price negotiations on manufacturer go-to-market strategies and decision-making, and the industry’s response to the wider dialogue on pricing transparency.